Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
NovoNorm, Prandin, Surepost, repaglinide (SMP-508)
print preview
bookmark
share with colleague
General Information
Company
Novo Nordisk A/S
Description
Short-acting beta cell stimulating meglitinide
Molecular Target
ATP-dependent potassium channel (KATP)
Mechanism of Action
ATP-dependent potassium channel (KATP) blocker
Latest Stage of Development
Marketed
Indication
Diabetes
Partner
Dainippon Sumitomo Pharma Co. Ltd.
;
Shionogi & Co. Ltd.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information